Biovica International AB (publ) (BIOVIC-B.ST)
SEK 1.62
(-8.47%)
SEK 1.62
(-8.47%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.29 Million SEK | 115.43% |
| 2022 | 3.38 Million SEK | 65.48% |
| 2021 | 2.04 Million SEK | -1.54% |
| 2020 | 2.07 Million SEK | 24.3% |
| 2019 | 1.67 Million SEK | -44.39% |
| 2018 | 3 Million SEK | 10.36% |
| 2017 | 2.72 Million SEK | 330.85% |
| 2016 | 632 Thousand SEK | -74.01% |
| 2015 | 2.43 Million SEK | 429.85% |
| 2014 | 459 Thousand SEK | -88.65% |
| 2013 | 4.04 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.71 Million SEK | -9.74% |
| 2023 FY | 7.29 Million SEK | 115.43% |
| 2023 Q3 | 1.07 Million SEK | -58.06% |
| 2023 Q1 | 1.75 Million SEK | 198.81% |
| 2023 Q2 | 2.56 Million SEK | 46.12% |
| 2023 Q4 | 1.89 Million SEK | 76.65% |
| 2022 Q2 | 961 Thousand SEK | 76.33% |
| 2022 FY | 3.38 Million SEK | 65.48% |
| 2022 Q4 | 587 Thousand SEK | -54.53% |
| 2022 Q3 | 1.29 Million SEK | 34.34% |
| 2022 Q1 | 545 Thousand SEK | -49.63% |
| 2021 Q2 | 268 Thousand SEK | -29.66% |
| 2021 FY | 2.04 Million SEK | -1.54% |
| 2021 Q1 | 381 Thousand SEK | 19.81% |
| 2021 Q4 | 1.08 Million SEK | 244.59% |
| 2021 Q3 | 314 Thousand SEK | 17.16% |
| 2020 FY | 2.07 Million SEK | 24.3% |
| 2020 Q2 | 44 Thousand SEK | -87.06% |
| 2020 Q3 | 1.37 Million SEK | 3027.27% |
| 2020 Q4 | 318 Thousand SEK | -76.89% |
| 2020 Q1 | 340 Thousand SEK | -78.62% |
| 2019 Q2 | 1.24 Million SEK | 240.33% |
| 2019 Q3 | 55 Thousand SEK | -95.6% |
| 2019 Q1 | 367 Thousand SEK | -78.86% |
| 2019 FY | 1.67 Million SEK | -44.39% |
| 2019 Q4 | 1.59 Million SEK | 2790.91% |
| 2018 Q1 | 914 Thousand SEK | -36.22% |
| 2018 FY | 3 Million SEK | 10.36% |
| 2018 Q4 | 1.73 Million SEK | 502.78% |
| 2018 Q3 | 288 Thousand SEK | 323.53% |
| 2018 Q2 | 68 Thousand SEK | -92.56% |
| 2017 Q2 | 133 Thousand SEK | -87.97% |
| 2017 Q1 | 1.1 Million SEK | 713.24% |
| 2017 FY | 2.72 Million SEK | 330.85% |
| 2017 Q4 | 1.43 Million SEK | 2709.8% |
| 2017 Q3 | 51 Thousand SEK | -61.65% |
| 2016 Q3 | 37 Thousand SEK | -80.53% |
| 2016 FY | 632 Thousand SEK | -74.01% |
| 2016 Q4 | 136 Thousand SEK | 267.57% |
| 2016 Q2 | 190 Thousand SEK | -29.37% |
| 2016 Q1 | 269 Thousand SEK | -83.57% |
| 2015 Q4 | 1.63 Million SEK | 0.0% |
| 2015 Q2 | 1.92 Million SEK | 0.0% |
| 2015 Q1 | 1.92 Million SEK | 0.0% |
| 2015 FY | 2.43 Million SEK | 429.85% |
| 2015 Q3 | 1.63 Million SEK | -15.09% |
| 2014 FY | 459 Thousand SEK | -88.65% |
| 2013 FY | 4.04 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 87.454% |
| Ziccum AB (publ) | 3.74 Million SEK | -94.556% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 98.817% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | 85.56% |
| Mendus AB (publ) | 28.48 Million SEK | 74.409% |
| Genovis AB (publ.) | 158.23 Million SEK | 95.393% |
| Intervacc AB (publ) | 8.01 Million SEK | 9.046% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -66.667% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 95.723% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | 83.393% |
| Aptahem AB (publ) | 2.63 Million SEK | -177.118% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -604.348% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -9367.532% |
| Fluicell AB (publ) | 3.33 Million SEK | -118.394% |
| Saniona AB (publ) | 16.84 Million SEK | 56.71% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | 55.568% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -505.985% |
| AcouSort AB (publ) | 10.55 Million SEK | 30.907% |
| Xintela AB (publ) | 78 Thousand SEK | -9246.154% |
| Abliva AB (publ) | 137 Thousand SEK | -5221.168% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 87.344% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -261.966% |
| OncoZenge AB (publ) | 3000.00 SEK | -242900.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -4603.226% |
| CombiGene AB (publ) | 5.54 Million SEK | -31.491% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 99.396% |
| Camurus AB (publ) | 1.71 Billion SEK | 99.575% |
| Corline Biomedical AB | 25.03 Million SEK | 70.875% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -28.39% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -911.096% |
| I-Tech AB | 120.86 Million SEK | 93.968% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 94.564% |
| Cyxone AB (publ) | 5.14 Million SEK | -41.608% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -3.404% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | 31.644% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | 35.085% |
| Nanologica AB (publ) | 1.44 Million SEK | -405.198% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -13654.717% |
| BioInvent International AB (publ) | 71.46 Million SEK | 89.799% |
| Alzinova AB (publ) | 270 Thousand SEK | -2600.0% |
| Oncopeptides AB (publ) | 35.22 Million SEK | 79.302% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -398.284% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -158.327% |
| Simris Alg AB (publ) | 4.35 Million SEK | -67.432% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -5507.692% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 96.946% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -31595.652% |